R. Luqmani

Matthew J. Thompson, C. Heneghan, A. Plüddemann, 2013, The British journal of general practice : the journal of the Royal College of General Practitioners.

Autoantibodies Against Lysosome Associated Membrane Protein-2 (LAMP-2) in Pediatric Chronic Primary Systemic Vasculitis

C. Ross, K. Brown, R. Luqmani, 2021, Frontiers in Immunology.

A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.

K. Kalunian, P. Merkel, J. Stone, 2002, Arthritis and rheumatism.

Reuma.pt/vasculitis – the Portuguese vasculitis registry

J. Branco, M. Santos, H. Canhão, 2020, Orphanet Journal of Rare Diseases.

Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis

P. Merkel, L. Moreland, K. Maksimowicz-McKinnon, 2020, Arthritis care & research.

Nomenclature of Cutaneous Vasculitis

P. Merkel, J. Callen, S. Kawana, 2018, Arthritis & rheumatology.

Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS).

R. Luqmani, D. Nakagomi, D. Jayne, 2017, Clinical and experimental rheumatology.

Giant Cell Arteritis and Takayasu Arteritis: Are they a different spectrum of the same disease?

R. Luqmani, J. Sznajd, B. Seeliger, 2015 .

Time to focus on outcome assessment tools for childhood vasculitis

S. Ozen, A. Karaoğlu, R. Luqmani, 2011, Pediatric rheumatology online journal.

DCVAS ACR/EULAR endorsed study to develop classification and diagnostic criteria for primary systemic vasculitis

R. Luqmani, 2010 .

Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss

A. Tomelleri, R. Luqmani, W. Schmidt, 2020, Rheumatology.

European Headache Federation recommendations for neurologists managing giant cell arteritis

J. Versijpt, R. Luqmani, A. Sinclair, 2020, The Journal of Headache and Pain.

2018 Update of the EULAR recommendations for the management of large vessel vasculitis

C. Turesson, F. Buttgereit, G. Hatemi, 2019, Annals of the rheumatic diseases.

of large vessel vasculitis EULAR recommendations for the management

H. Raspe, D. Scott, R. Luqmani, 2009 .

Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future

R. Luqmani, S. Monti, B. Hellmich, 2020, Current Rheumatology Reports.

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis

F. Buttgereit, R. Luqmani, S. Monti, 2019, RMD Open.

Giant cell arteritis: Current treatment and management.

Ana Filipa Rodrigues, R. Luqmani, C. Ponte, 2015, World journal of clinical cases.

Pharmacotherapy of vasculitis

R. Luqmani, M. Chan, 2009, Expert opinion on pharmacotherapy.

Treatment of Polymyalgia Rheumatica and Giant Cell Arteritis: Are We Any Further Forward?

R. Luqmani, 2007, Annals of Internal Medicine.

Mortality in systemic vasculitis: a systematic review.

R. Luqmani, R. Phillip, 2008, Clinical and experimental rheumatology.

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis

F. Buttgereit, R. Luqmani, S. Monti, 2019, RMD Open.

Giant Cell Arteritis

R. Luqmani, A. Awisat, 2020, Rheumatic Disease in Geriatrics.

Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis

J. Fonseca, C. Montecucco, R. Luqmani, 2021, Annals of the Rheumatic Diseases.

Magnetic resonance angiography versus 18F-fluorodeoxyglucose positron emission tomography in large vessel vasculitis.

D. Blockmans, R. Luqmani, C. Salvarani, 2019, Autoimmunity reviews.

The association of vascular risk factors with visual loss in giant cell arteritis

P. Merkel, J. Robson, R. Luqmani, 2016, Rheumatology.

Systemic vasculitis--is it time to reclassify?

P. Merkel, R. Luqmani, R. Suppiah, 2011, Rheumatology.

The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis

M. Briel, M. Walter, A. Tyndall, 2012, European Journal of Nuclear Medicine and Molecular Imaging.

Update on the use of biologics in primary systemic vasculitides

R. Luqmani, C. Mukhtyar, A. Chan, 2007, Expert review of clinical immunology.

Clinical and biological assessment in systemic necrotizing vasculitides.

R. Luqmani, C. Mukhtyar, O. Flossmann, 2006, Clinical and experimental rheumatology.

Discontinuation of therapies in vasculitis.

R. Luqmani, 2013, Clinical and experimental rheumatology.

Disease assessment in systemic vasculitis.

R. Luqmani, 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Treat-to-target in vasculitis: is this a sensible approach?

R. Luqmani, 2012, Clinical and experimental rheumatology.

Immunopharmacology of Vasculitic Syndromes

D. Adu, P. Bacon, R. Luqmani, 1992 .

Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.

P. Merkel, C. Kallenberg, E. Matteson, 2011, Journal of the American Society of Nephrology.

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis

P. Merkel, J. Dawson, J. Shea, 2017, Rheumatology International.

State of the Art in the Treatment of Systemic Vasculitides

R. Luqmani, 2014, Front. Immunol..

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis.

D. Adu, P. Emery, P. Bacon, 1997, QJM : monthly journal of the Association of Physicians.

Azathioprine, cyclophosphamide and chlorambucil.

P. Bacon, R. Luqmani, R. Palmer, 1990, Bailliere's clinical rheumatology.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

P. van Paassen, V. Tesar, C. Savage, 2010, The New England journal of medicine.

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary.

D. D'cruz, N. Basu, A. Salama, 2020, Rheumatology.

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

P. Merkel, M. Weisman, M. Nodale, 2020, Annals of the Rheumatic Diseases.

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines.

D. D'cruz, N. Basu, A. Salama, 2020, Rheumatology.

The European Vasculitis Society 2016 Meeting Report

Kazuo Suzuki, A. Vaglio, A. Salama, 2017, Kidney international reports.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

P. van Paassen, V. Tesar, C. Savage, 2015, Annals of the rheumatic diseases.

Maintenance of clinical remission in ANCA-associated vasculitis

R. Luqmani, 2013, Nature Reviews Rheumatology.

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

I. Bruce, D. Scott, D. D'cruz, 2012, Rheumatology.

Damage Assessment in ANCA-Associated Vasculitis

R. Luqmani, K. Bhamra, 2012, Current Rheumatology Reports.

Pulmonary-renal syndromes: an update for respiratory physicians.

R. Luqmani, C. McCabe, Q. Jones, 2011, Respiratory medicine.

Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

C. Gordon, D. Adu, G. Kitas, 1997, Arthritis and rheumatism.

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

S. Yancey, P. Merkel, F. Moosig, 2017, The New England journal of medicine.

Mortality in Wegener's granulomatosis: a bimodal pattern.

N. Arden, C. Edwards, R. Luqmani, 2011, Rheumatology.

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting

R. Stimson, R. Luqmani, J. Coia, 2001 .

Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, Z. C. Chiesa Fuxench, R. Luqmani, 2020, Arthritis & rheumatology.

Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides

P. Merkel, R. Luqmani, A. Bischof, 2019, Neurology: Neuroimmunology & Neuroinflammation.

Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway.

W. Koldingsnes, R. Luqmani, R. Watts, 2019, Rheumatology.

Small- and Medium-Vessel Primary Vasculitis

R. Luqmani, A. Águeda, L. O’neill, 2019, Clinical Immunology.

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody–associated vasculitis

P. Merkel, R. Luqmani, R. Watts, 2017, Rheumatology.

Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.

P. Merkel, C. Kallenberg, E. Matteson, 2011, Arthritis and rheumatism.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

Clinical features and structured clinical evaluation of vasculitis.

R. Luqmani, A. Águeda, C. Ponte, 2018, Best practice & research. Clinical rheumatology.

Chapter 90 – Polyarteritis Nodosa and Related Disorders

R. Luqmani, 2017 .

Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?

P. Merkel, A. Judge, J. Robson, 2017, Rheumatology.

90 – Polyarteritis Nodosa and Related Disorders

R. Luqmani, 2013 .

Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis

P. Merkel, C. Kallenberg, E. Matteson, 2011, Annals of the rheumatic diseases.

Clinical associations of renal involvement in ANCA-associated Vasculitis.

P. Merkel, G. Mayer, L. Quintana, 2020, Autoimmunity reviews.

Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index

P. Merkel, V. Tesar, A. Vaglio, 2010, Annals of the rheumatic diseases.

Medical student appraisal of interactive computer‐assisted learning programs embedded in a general pathology course

M. Arends, G. Watson, R. Luqmani, 2000, The Journal of pathology.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target

P. Bowness, R. Luqmani, R. Cornall, 2012, Clinical & developmental immunology.

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis

P. Tugwell, J. Farrar, P. Merkel, 2017, The Journal of Rheumatology.

The Journal of Rheumatology associated Vasculitis − Antineutrophil Cytoplasmic Antibody OMERACT Endorsement of Patient-reported Outcome Instruments in

P. Tugwell, J. Farrar, P. Merkel, 2017 .

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis

D. Blockmans, R. Luqmani, W. Schmidt, 2020, Rheumatology and Therapy.

A multicenter placebo-controlled study of methotrexate (MTX) in giant cell arteritis (GCA).

K. Kalunian, P. Merkel, J. Stone, 2000 .

Rho Kinase Expression in Giant Cell Arteritis: Validating Phosphorylated Ezrin/Radixin/Moesin Intensity Score to Increase Sensitivity of Temporal Artery Biopsy

N. Narula, D. Pisapia, R. Luqmani, 2022, The Journal of Rheumatology.

Tumor Necrosis Factor–Blocking Agents in Polymyalgia Rheumatica and Giant Cell Arteritis

R. Luqmani, 2008 .

Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort

P. Merkel, J. Robson, R. Luqmani, 2019, Arthritis & rheumatology.

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

R. Luqmani, D. Jayne, O. Flossmann, 2005, Annals of the rheumatic diseases.

The role of biologic therapies in the management of systemic vasculitis.

R. Luqmani, D. Jayne, C. Mukhtyar, 2006, Autoimmunity reviews.

Concise report Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis

G. Jones, D. Reid, G. Macfarlane, 2014 .

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients

A. Timms, S. Misbah, R. Luqmani, 2010, Journal of Clinical Pathology.

Measuring disease activity and outcomes in clinical studies.

R. Luqmani, 2002, Cleveland Clinic journal of medicine.

Assessing disease activity in the systemic vasculitides

R. Luqmani, 2002, Current opinion in rheumatology.

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis

J. Krischer, P. Merkel, J. Stone, 2008, Annals of the rheumatic diseases.

A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.

V. Tesar, A. Vaglio, A. Judge, 2011, Rheumatology.

S100A12 Serum Levels and PMN Counts Are Elevated in Childhood Systemic Vasculitides Especially Involving Proteinase 3 Specific Anti-neutrophil Cytoplasmic Antibodies

Kristen M. Gibson, C. Ross, D. Foell, 2018, Front. Pediatr..

Current state of tumour necrosis factor α blockade in Wegener’s granulomatosis

R. Luqmani, C. Mukhtyar, 2005 .

Speaker Abstracts (SP01–SP50)

M. Kaplan, P. Geusens, B. Rovin, 2012 .

Pseudoporphyria and Nonsteroidal Antiinflammatory Agents in Children with Juvenile Idiopathic Arthritis

R. Luqmani, O. Schofield, B. De Silva, 2000, Pediatric dermatology.

ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS)

P. Merkel, A. Judge, J. Robson, 2013, Clinical and Experimental Nephrology.

Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis.

C. Gordon, P. Emery, P. Bacon, 1994, British journal of rheumatology.

Classical versus non-renal Wegener's granulomatosis.

D. Scott, D. Adu, P. Emery, 1994, The Quarterly journal of medicine.

Rheumatoid factor testing in Spanish primary care: A population-based cohort study including 4.8 million subjects and almost half a million measurements

N. Arden, M. Javaid, R. Luqmani, 2019, Reumatología Clínica (English Edition).

Rheumatoid factor testing in Spanish primary care: A population-based cohort study including 4.8 million subjects and almost half a million measurements.

C. Cooper, N. Arden, M. Javaid, 2019, Reumatologia clinica.

The future of damage assessment in vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2007, The Journal of rheumatology.

The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis

J. Lamb, I. Bruce, B. Harrison, 2018, Rheumatology.

Towards diagnostic criteria for the ANCA-associated vasculitides.

R. Luqmani, 2007, Clinical and experimental rheumatology.

Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.

J. Krischer, D. Felson, P. Merkel, 2005, The Journal of rheumatology.

Disease assessment in systemic vasculitis

R. Luqmani, 2004 .

Cryofibrinogenaemia—a neglected disease

R. Luqmani, S. Moiseev, P. Novikov, 2016, Rheumatology.

Recurrent inflammatory stenosis of the M1 segment: diagnostic and therapeutic considerations

U. Schulz, D. Briley, R. Luqmani, 2012, Neuroradiology.

Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis.

R. Luqmani, D. Jayne, G. Gaskin, 2002 .

Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia

R. Luqmani, W. Schmidt, B. Dasgupta, 2020, Annals of the rheumatic diseases.

FRI0464 Development of the Classification Criteria for GIANT Cell Arteritis in the Diagnostic and Classification Criteria for Vasculitis Study: A Pilot Study Using A Panel Review Methodology

A. Judge, J. Robson, R. Luqmani, 2014 .

Development of comprehensive disease assessment in systemic vasculitis.

P. Bacon, K. De Groot, R. Luqmani, 2007, Annals of the rheumatic diseases.

An audit of the use of hydroxychloroquine in rheumatology clinics

R. Luqmani, S. Downes, Srilakshmi M Sharma, 2018, Rheumatology advances in practice.

FRI0195 ULTRASONOGRAPHIC HALO SCORE ASSOCIATES WITH INTIMAL HYPERPLASIA IN GIANT CELL ARTERITIS

R. Luqmani, W. Schmidt, B. Dasgupta, 2020, Annals of the Rheumatic Diseases.

Relapses in patients with a systemic vasculitis.

D. Adu, P. Emery, P. Bacon, 1993, The Quarterly journal of medicine.

Letter to the Editor (Matters Arising)

R. Luqmani, C. Deighton, D. Homer, 2008 .

Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes.

D. T. Gray, Janet A. Blood, I. Bruce, 2020, Rheumatology.

Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

D. Foell, R. Yeung, A. Huber, 2017, Arthritis & rheumatology.

Correlates of Disease, Function and Self-esteem in Juvenile Idiopathic Arthritis: A cross-sectional pilot study

R. Luqmani, A. Kerr, W. Uttley, 2000 .

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines.

D. D'cruz, N. Basu, A. Salama, 2020, Rheumatology.

Can We Identify Patients with Microscopic Polyangiitis Who Are at Risk of Relapse?

R. Luqmani, 2012, The Journal of Rheumatology.

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.

N. Arden, R. Luqmani, D. Jayne, 2011, Rheumatology.

Giant cell arteritis: new concepts, treatments and the unmet need that remains.

B. Griffiths, A. Morgan, S. Mackie, 2018, Rheumatology.

Early development of new cardiovascular risk factors in the systemic vasculitides.

P. Merkel, C. Klersy, C. Montecucco, 2019, Clinical and experimental rheumatology.

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

Hydroxychloroquine retinopathy: an emerging problem

R. Luqmani, S. Downes, M. Latasiewicz, 2017, Eye.

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)

R. Luqmani, E. Salisbury, J. McLaren, 2003 .

Necrotizing vasculitis--relapse despite cytotoxic therapy.

D. Adu, P. Emery, P. Bacon, 1993, Advances in experimental medicine and biology.

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.

P. Kiely, M. Lunt, F. Mckenna, 2011, Rheumatology.

Long-term damage to the ENT system in Wegener’s granulomatosis

R. Luqmani, D. Jayne, N. Rasmussen, 2011, European Archives of Oto-Rhino-Laryngology.

Missing laboratory test data in electronic general practice records: analysis of rheumatoid factor recording in the clinical practice research datalink

Kamal R Mahtani, Tim A Holt, K. Mahtani, 2015, Pharmacoepidemiology and drug safety.

Dermatological Addendum to the 2012 International Chapel Hill Consensus Conference Nomenclature of Vasculitides

P. Merkel, J. Callen, S. Kawana, 2017 .

Explaining fatigue in ANCA-associated vasculitis.

D. Reid, G. Macfarlane, Gareth T. Jones, 2013, Rheumatology.

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.

K. Chakravarty, D. Scott, D. D'cruz, 2014, Rheumatology.

A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis

P. Merkel, J. Stone, John C. Davis, 2011, Arthritis care & research.

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.

K. Chakravarty, D. Scott, D. D'cruz, 2007, Rheumatology.

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

H. Raspe, P. Merkel, D. Scott, 2006, Annals of the rheumatic diseases.

Design of the Wegener's Granulomatosis Etanercept Trial (WGET).

F. Martinez, C. Meinert, J. Stone, 2002, Controlled clinical trials.

Physiotherapy for children with hypermobility syndrome

R. Luqmani, A. Kerr, W. Uttley, 2000 .

2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis

P. Merkel, A. Judge, J. Robson, 2022, Arthritis & rheumatology.

The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.

M. Bradburn, A. Wailoo, C. Pease, 2016, Health technology assessment.

The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting.

R. Stimson, R. Luqmani, J. Coia, 2001, QJM : monthly journal of the Association of Physicians.

Long-term patient survival in ANCA-associated vasculitis

P. Höglund, C. Pusey, R. Luqmani, 2010, Annals of the rheumatic diseases.

Posterior scleritis--an unusual manifestation of Cogan's syndrome.

P. Emery, P. Murray, R. Luqmani, 1994, British journal of rheumatology.

Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease.

Manil D. Chouhan, R. Chapman, R. Sadler, 2020, Clinical medicine.

The role of neutrophils in rheumatic disease-associated vascular inflammation

I. Udalova, R. Luqmani, Lihui Wang, 2022, Nature Reviews Rheumatology.

ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies

I. Udalova, C. Monaco, R. Luqmani, 2020, JCI insight.

Disease assessment and management of the vasculitides.

G. Kitas, P. Bacon, A. Exley, 1997, Bailliere's clinical rheumatology.

Full Review Disease assessment in systemic vasculitis

R. Luqmani, 2015 .

A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

P. Merkel, J. Stone, Y. Min, 2001, Arthritis and rheumatism.

Necrotic granulomatous pseudotumours in bilateral resurfacing hip arthoplasties: evidence for a type IV immune response

M. Vlychou, D. Crook, D. Murray, 2008, Virchows Archiv.

Is it possible to offer evidence-based treatment for systemic vasculitis?: Editorial review

R. Luqmani, 2000, Scandinavian journal of rheumatology.

How to diagnose and treat secondary forms of vasculitis.

R. Luqmani, S. Pathare, T. Kwok-Fai, 2005, Best practice & research. Clinical rheumatology.

Development of comprehensive disease assessment in systemic vasculitis

P. Bacon, R. Luqmani, D. Jayne, 2007 .

Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink.

K. Mahtani, T. Holt, R. Luqmani, 2015, Rheumatology.

Maternal Stressors, Maternal Wellbeing and Children's Wellbeing in the Context of Juvenile Idiopathic Arthritis

C. Wright, K. Shaw, J. Barlow, 2002 .

2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative

A. Iagnocco, E. Matteson, R. Marcus, 2012, Annals of the rheumatic diseases.

Two cases of 'Wegener's tuberculosis'.

C. Gordon, P. Emery, A. Howie, 1993, British journal of rheumatology.

EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

P. Merkel, A. Vaglio, O. Karadag, 2023, Annals of the Rheumatic Diseases.

The characterisation and determinants of quality of life in ANCA associated vasculitis

D. Reid, G. Macfarlane, N. Basu, 2013, Annals of the rheumatic diseases.

Acute pancreatitis with pseudocyst formation in a patient with polyarteritis nodosa.

R. Luqmani, W. Beadles, P. Welsby, 2005, The Journal of rheumatology.

ANCA POSITIVE AND ANCA NEGATIVE MICROSCOPIC POLYARTERITIS

D. Adu, P. Bacon, A. Howie, 1994 .

Cardiovascular involvement in primary systemic vasculitis.

R. Luqmani, C. Mukhtyar, P. Brogan, 2009, Best practice & research. Clinical rheumatology.

Ocular manifestations of classical and limited Wegener's granulomatosis.

P. Murray, P. Stavrou, R. Luqmani, 1993, The Quarterly journal of medicine.

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis

Shigeto Kobayashi, John McLaren, David Jayne, 2010, Annals of the rheumatic diseases.

Inner ear deafness in Wegener's granulomatosis.

D. Adu, P. Emery, R. Jubb, 1991, The Journal of rheumatology.

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).

R. Luqmani, D. Jayne, 1999 .

An unusual cause of death in Wegener’s granulomatosis

R. Luqmani, C. Hall, S. Kamalı, 2006, Annals of the rheumatic diseases.

Comparison of disease activity measures for ANCA-associated vasculitis.

J. Krischer, P. Merkel, J. Stone, 2004 .

Introduction to, and classification of, the systemic vasculitides.

R. Luqmani, H. Robinson, Helen Robinson, 2001, Best practice & research. Clinical rheumatology.

Deoxyspergualin in relapsing and refractory Wegener’s granulomatosis

V. Tesar, P. Heinzel, A. Bruchfeld, 2008, Annals of the rheumatic diseases.

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in "non-renal" AbCA-associated vasculitis.

C. Feighery, P. Bacon, R. Luqmani, 2002 .

CUTANEOUS MANIFESTATIONS OF ANCA-ASSOCIATED VASCULITIS

P. Merkel, R. Luqmani, R. Watts, 2016 .

Different Disease Endotypes in Phenotypically Similar Vasculitides Affecting Small-to-Medium Sized Blood Vessels

Erin E. Gill, Kristen M. Gibson, C. Ross, 2021, Frontiers in Immunology.

A hidden lung cancer in a patient with granulomatosis with polyangiitis

H. Peschl, R. Luqmani, R. Benamore, 2020, BJR case reports.

Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases.

R. Luqmani, J. Sznajd, C. Ponte, 2014, Clinical and experimental rheumatology.

Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9

P. Merkel, M. Boers, T. Neogi, 2009, The Journal of Rheumatology.

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire

P. Merkel, H. Doll, J. Dawson, 2018, Annals of the rheumatic diseases.

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.

D. Reid, G. Macfarlane, N. Basu, 2014, Rheumatology.

Assessment of damage in vasculitis: expert ratings of damage.

P. Merkel, R. Luqmani, D. Jayne, 2009, Rheumatology.

Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)

S. Özen, R. Cimaz, R. Luqmani, 2012, Annals of the rheumatic diseases.

Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides.

E. Hoppenreijs, N. Wulffraat, S. Ozen, 2012, Clinical and experimental rheumatology.

Pulmonary Involvement in Primary Systemic Vasculitides.

P. Merkel, J. Robson, R. Luqmani, 2021, Rheumatology.

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis

R. Luqmani, B. Hellmich, O. Flossmann, 2007 .

Diagnosis and assessment of systemic vasculitis.

R. Luqmani, E. Mcrorie, J. McLaren, 2002, Clinical and experimental rheumatology.

The RUDY study platform – a novel approach to patient driven research in rare musculoskeletal diseases

J. Barrett, M. K. Javaid, C. Cooper, 2016, Orphanet Journal of Rare Diseases.

A Multicenter, Randomized, Placebo‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis

I. Bruce, D. Symmons, P. Macfarlane, 2019, Arthritis & Rheumatology.

Textbook of orthopaedics, trauma, and rheumatology /

J. Robb, R. Luqmani, D. Porter, 2008 .

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study

J. Barrett, N. Basu, A. Salama, 2021, Arthritis & rheumatology.

Listeria monocytogenes infection in a prosthetic knee joint in rheumatoid arthritis.

R. Luqmani, M. T. Walters, M. Cawley, 1990, Annals of the rheumatic diseases.

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.

N. Arden, A. Kiran, J. Robson, 2015, Annals of the rheumatic diseases.

DISEASE‐MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: CURRENT CONCEPTS

C. Gordon, P. Emery, R. Luqmani, 1994, The British journal of clinical practice.

Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study

N. Arden, A. Kiran, J. Robson, 2016, The Journal of Rheumatology.

OP0055 ULTRASOUND HALO SIGN AS A POTENTIAL MONITORING TOOL FOR PATIENTS WITH GIANT CELL ARTERITIS: A PROSPECTIVE ANALYSIS

J. Fonseca, C. Montecucco, R. Luqmani, 2021 .

The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice

R. Luqmani, S. Monti, W. Schmidt, 2017, Rheumatology.

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?

J. Morlet, R. Luqmani, A. Hutchings, 2017, RMD Open.

The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis

P. Merkel, M. Boers, G. Tómasson, 2011, The Journal of Rheumatology.

2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

A. Iagnocco, H. Kremers, E. Matteson, 2012, Arthritis and rheumatism.

Cerebrovascular Disease ? A Clinical Practice Research Datalink Study Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or

N. Arden, A. Kiran, R. Luqmani, 2016 .

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.

P. Kiely, M. Lunt, F. Mckenna, 2010, Rheumatology.

Patient-reported Outcomes in Polymyalgia Rheumatica

A. Iagnocco, E. Matteson, R. Marcus, 2012, The Journal of Rheumatology.

Activity and Damage

R. Luqmani, 2019, Rare Diseases of the Immune System.

Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda

P. Merkel, M. Boers, E. Matteson, 2011, Journal of Rheumatology.

P. Merkel, R. Luqmani, D. Jayne, 2011, Arthritis care & research.

Assessment of Disease Activity and Damage

R. Luqmani, 2014 .

Birmingham Vasculitis Activity Score

R. Moots, D. Adu, P. Emery, 1993 .

Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).

D. Scott, R. Luqmani, J. Ledingham, 2006, Rheumatology.

Updating the BSR Guidelines for Anti-TNF therapy in Adult RA (again)

R. Luqmani, J. Ledingham, C. Deighton, 2006 .

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.

R. Luqmani, D. Jayne, B. Hellmich, 2006, Clinical and experimental rheumatology.

factors for severe outcomes in patients with systemic vasculitis & COVID-19: a bi-national registry-based cohort study

J. Barrett, N. Basu, A. Salama, 2021 .

2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis

P. Merkel, A. Judge, J. Robson, 2022, Arthritis & rheumatology.

Making the most of the waiting room: Electronic patient engagement, a mixed methods study

M. South, J. Kaye, V. Coathup, 2018, Digital health.

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS

H. Doll, P. Höglund, J. Robson, 2012 .

SAT0619-HPR AN AUDIT OF GLUCOCORTICOID PRESCRIPTION IN PATIENTS WITH GIANT CELL ARTERITIS

R. Luqmani, L. O’neill, A. Awisat, 2020 .

Outcome measures in ANCA-associated vasculitis.

J. Robson, R. Luqmani, R. Suppiah, 2010, Rheumatic diseases clinics of North America.

Outcome in small-vessel systemic vasculitis.

R. Luqmani, O. Flossmann, 2006, The Journal of rheumatology.

Functional outcome vs damage in systemic vasculitis

G. Kitas, P. Bacon, A. Exley, 1996 .

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV

G. Tómasson, R. Luqmani, S. Monti, 2023, RMD Open.

Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis.

R. Luqmani, A. Mahr, I. Bajema, 2023, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Updates on the diagnosis and monitoring of giant cell arteritis

C. Montecucco, R. Luqmani, S. Monti, 2023, Frontiers in Medicine.

The provisional OMERACT ultrasonography score for giant cell arteritis

A. Iagnocco, E. Naredo, M. Aschwanden, 2022, Annals of the Rheumatic Diseases.

NEGATIVE RHEUMATOID FACTOR IN PRIMARY CARE DELAYS REFERRAL OF PATIENTS WITH RHEUMATOID ARTHRITIS

K. Mahtani, T. Holt, R. Luqmani, 2014 .

Assessing ACR/EULAR Provisional 2017 Classification Criteria for Granulomatosis with Polyangiitis (GPA) in a Cohort of 376 Children with Small to Medium Vessel Chronic Vasculitis - a Pediatric Vasculitis Initiative (PedVas) Study

R. Luqmani, D. Cabral, K. Morishita, 2017 .

SAT0286 Paediatric Vasculitis Damage Index: A New Tool for Standardised Disease Assessment

S. Özen, R. Cimaz, R. Luqmani, 2014 .

Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis

J. Farrar, P. Merkel, L. Moreland, 2019, The Journal of Rheumatology.

083. COMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASU’S ARTERITIS AND GIANT CELL ARTERITIS

P. Merkel, L. Moreland, K. Maksimowicz-McKinnon, 2019, Rheumatology.

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis

G. Tómasson, R. Luqmani, S. Monti, 2023, RMD Open.

Pulse vs daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial

V. Tesar, C. Pusey, C. Savage, 2009 .

The HAVEN study—hydroxychloroquine in ANCA vasculitis evaluation—a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan

D. D'cruz, S. Sangle, A. Douiri, 2023, Trials.

Prevalence and associations of peripheral neuropathy at disease-onset in ANCA-associated vasculitides: Data from DCVAS study

R. Luqmani, A. Bischof, R. Suppiah, 2018 .

077. CLASSIFICATION CRITERIA FOR LARGE-VESSEL VASCULITIS

P. Merkel, A. Judge, J. Robson, 2019, Rheumatology.

Association Between HLA–DPB1 and Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in Children

C. Ross, D. Foell, J. Graham, 2023 .

An audit of the use of hydroxychloroquine in rheumatology clinics

R. Luqmani, S. Downes, Srilakshmi M Sharma, 2018, Rheumatology advances in practice.

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

S. Tuck, B. Harrison, B. Griffiths, 2022, Rheumatology.

RHEUMATOID FACTOR TESTING IN SPANISH PRIMARY CARE COSTS (sic)1432 PER TRUE POSITIVE CASE OF RHEUMATOID ARTHRITIS; A STUDY USING ELECTRONIC DATA FROM THE INFORMATION SYSTEM FOR THE DEVELOPMENT OF RESEARCH IN PRIMARY CARE

N. Arden, C. Edwards, R. Luqmani, 2015 .

Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

W. Dixon, I. Bruce, Paul Wordsworth, 2013, The Pharmacogenomics Journal.

Developing multidisciplinary guidelines for the management of early rheumatoid arthritis.

R. Luqmani, S. Hennell, 2008, Musculoskeletal care.

AN EDITION OF GREEK RHEUMATOLOGY SOCIETY AND PROFESSIONAL ASSOCIATION OF RHEUMATOLOGISTS

R. Moots, A. Iagnocco, E. Naredo, 2017 .

A Multicenter, Randomized, Placebo‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis

I. Bruce, D. Symmons, P. Macfarlane, 2019, Arthritis & Rheumatology.

Current Status of Outcome Measure Development in Vasculitis

P. Merkel, M. Boers, E. Matteson, 2014, The Journal of Rheumatology.

OP0142 THE IMPACT OF DISEASE EXTENT AND SEVERITY DETECTED BY QUANTITATIVE ULTRASOUND ANALYSIS IN THE DIAGNOSIS AND OUTCOME OF GIANT CELL ARTERITIS: RESULTS FROM THE TEMPORAL ARTERYBIOPSY VERSUS ULTRASOUND (TABUL) STUDY AND VALIDATION IN AN INDEPENDENT COHORT

R. Caporali, C. Klersy, C. Montecucco, 2019, Oral Presentations.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

P. van Paassen, V. Tesar, C. Savage, 2010, The New England journal of medicine.

The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target

P. Bowness, R. Luqmani, R. Cornall, 2012, Clinical & developmental immunology.

Development of comprehensive disease assessment in systemic vasculitis

P. Bacon, R. Luqmani, D. Jayne, 2006, Postgraduate Medical Journal.

Association Between HLA–DPB1 and Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in Children

D. Foell, J. Graham, B. Drögemöller, 2022, Arthritis & rheumatology.

The validity of surrogate markers in rheumatic disease.

P. Emery, R. Luqmani, 1993, British journal of rheumatology.

The characterisation and determinants of quality of life in ANCA associated vasculitis

D. Reid, G. Macfarlane, N. Basu, 2013, Annals of the rheumatic diseases.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

V. Tesar, A. Vaglio, B. Crestani, 2016, Annals of the rheumatic diseases.

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.

K. Chakravarty, D. D'cruz, R. Luqmani, 2007, Rheumatology.

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal

C. Carroll, P. Tappenden, N. Latimer, 2014, PharmacoEconomics.

AB0607 SELF-MANAGEMENT BEHAVIOURS IN ANCA-ASSOCIATED VASCULITIS: SECONDARY ANALYSIS OF INTERVIEW DATA

J. Robson, N. Milman, P. Cronholm, 2019, Abstracts accepted for Publication.

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.

N. Arden, R. Luqmani, D. Jayne, 2011, Rheumatology.

Update on the use of biologics in primary systemic vasculitides

R. Luqmani, C. Mukhtyar, A. Chan, 2007, Expert review of clinical immunology.

An audit of the use of hydroxychloroquine in rheumatology clinics Rheumatology Advances in Practice

R. Luqmani, S. Downes, Srilakshmi M Sharma, 2018 .

EULAR recommendations for the management of primary small and medium vessel vasculitis

H. Raspe, C. Kallenberg, David Steven Scott, 2008, Annals of the rheumatic diseases.

2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

A. Iagnocco, H. Kremers, E. Matteson, 2012, Arthritis and rheumatism.

Nomenclature and classification of vasculitis – update on the ACR/EULAR Diagnosis and Classification of Vasculitis Study (DCVAS)

P. Merkel, R. Luqmani, R. Suppiah, 2011, Clinical and experimental immunology.

A Multicenter, Randomized, Placebo‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis

I. Bruce, D. Symmons, P. Macfarlane, 2019, Arthritis & rheumatology.

Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study

N. Arden, A. Kiran, J. Robson, 2016, The Journal of Rheumatology.

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts

V. Tesar, A. Vaglio, B. Crestani, 2017, RMD Open.

Can We Identify Patients with Microscopic Polyangiitis Who Are at Risk of Relapse?

R. Luqmani, 2012, The Journal of Rheumatology.

Assessment of systemic vasculitis.

N. Basu, R. Luqmani, Anne Miller, 2008, Autoimmunity reviews.

FRI0286 CUTANEOUS POLYARTERITIS NODOSA: A SUBSET OF SYSTEMIC PAN OR A DISEASE APART?

F. Buttgereit, R. Luqmani, S. Monti, 2019, Poster Presentations.

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK

N. Arden, A. Kiran, J. Robson, 2013 .

Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9

M. Boers, T. Neogi, R. Luqmani, 2009, The Journal of Rheumatology.

Stroke frequency, associated factors, and clinical features in primary systemic vasculitis: a multicentric observational study

J. Putaala, N. Hammam, R. Luqmani, 2024, Journal of neurology.

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

M. Nodale, L. Moreland, C. Pusey, 2023, Annals of the Rheumatic Diseases.

The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.

F. Pieruzzi, B. Rovin, V. Strand, 2023, The Lancet. Rheumatology.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

P. van Paassen, V. Tesar, C. Savage, 2015, Annals of the rheumatic diseases.

Inter-Rater Analysis of Ultrasound and Histological Findings in Patients with Suspected Giant Cell Arteritis

M. Bradburn, A. Wailoo, C. Pease, 2015 .

Polymyalgia rheumatica shows metabolomic alterations that are further altered by glucocorticoid treatment: Identification of metabolic correlates of fatigue.

R. Luqmani, H. McGettrick, J. Manning, 2024, Journal of autoimmunity.

University of Birmingham Polymyalgia rheumatica shows metabolomic alterations that are further altered by glucocorticoid treatment

R. Luqmani, H. McGettrick, J. Manning, 2022 .

Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis

R. Luqmani, Z. Hruskova, Arthur White, 2024, RMD open.